about
Synthesis of novel Ral inhibitors: An in vitro and in vivo studyRAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunctionThe Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.Therapeutic Approaches to RAS Mutation.Cancer stem cell drugs target K-ras signaling in a stemness context.Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.Modeling of RAS complexes supports roles in cancer for less studied partners.Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Calmodulin and PI3K Signaling in KRAS Cancers.Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.A New View of Pathway-Driven Drug Resistance in Tumor Proliferation.Intrinsic protein disorder in oncogenic KRAS signaling.Identification of Differentially Expressed K-Ras Transcript Variants in Patients With Leiomyoma.Independent and core pathways in oncogenic KRAS signaling.Quantification of spatiotemporal patterns of Ras isoform expression during development.Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation.Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains.The dynamic mechanism of RASSF5 and MST kinase activation by Ras.Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity.Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibilityExploring prognostic genes in ovarian cancer stage-related coexpression network modules
P2860
Q28817036-3E0843A8-3A93-4C79-B564-06C37C39624BQ36580617-6C6FFBE9-4055-418E-AC4F-B3A62C3156B0Q36606151-B100D7AE-F4ED-4B31-8FD8-B234DFA2AA7AQ37122874-230D0358-96CC-46C3-B6A1-89D51EC9B650Q37325194-7E6EF885-ACE5-4BD5-B91D-4DB696A610AEQ37398069-F80F2333-4BDF-4D65-BEA1-E2DF6C0A21F2Q38641385-45E9326E-418B-41DB-9222-0BB74C4D8450Q38721757-E1B9CBB2-C047-43B6-879E-55E4C7468C55Q38731776-C92969DE-84C3-44BA-B321-2AE51E7BEC0DQ38809850-960B7257-7080-4AA6-9D0F-0B2C332AA132Q38891078-B3480C69-8168-43F0-95E8-71A9287C2375Q38891257-DEBF890D-313C-44D0-8254-BE44F810EB08Q39155018-0E84082D-6797-4463-9F5C-76D3E56950A6Q39361391-D133217C-B8F8-4BBA-82B7-B5926E22EB8BQ40364754-F5014BE1-463F-4EE6-9D6B-457DB0D3FC00Q40968374-86725AD6-8DAF-4B8F-9781-BE4976F374C8Q42328354-3185F062-852A-4616-88C3-5957B463F69FQ47144061-8D311E4B-B0DB-4E75-A9F2-423D66CF96F7Q47424576-2A599FE2-D75C-46B5-A441-54B0E7A18B3FQ47566645-6201B264-092F-4B1F-80D0-979F49D67A85Q50025866-277987A4-1205-412A-A1F7-BF2DB564D391Q52611910-4878BE47-2E1D-469F-8F88-FA2D55FD6194Q56342454-737C1EB9-C90E-4196-85CB-8754876CF75AQ58706435-0FAE230B-57C4-4438-A280-07378403B452
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A New View of Ras Isoforms in Cancers.
@ast
A New View of Ras Isoforms in Cancers.
@en
type
label
A New View of Ras Isoforms in Cancers.
@ast
A New View of Ras Isoforms in Cancers.
@en
prefLabel
A New View of Ras Isoforms in Cancers.
@ast
A New View of Ras Isoforms in Cancers.
@en
P2093
P2860
P1433
P1476
A New View of Ras Isoforms in Cancers.
@en
P2093
Chung-Jung Tsai
Hyunbum Jang
Mayukh Chakrabarti
P2860
P356
10.1158/0008-5472.CAN-15-1536
P407
P577
2015-12-10T00:00:00Z